Pre-ASCO China Webinar #3-Clinical Trial Consortium&Global Oncology Drug Dev

3rd of the "Pre-ASCO China Summit" series. Join Zoom Webinar by Clicking: Webinar ID: 837 1681 9973

About this Event

Corporate groups and clinical trial consortium have played important roles in advancing novel anti-cancer therapies and standardizing treatment regimens. They provide large network with broad patient catchment and the capability to operate on shared quality standards. We invited Prof. Yi-Long Wu and Prof. Karen Kelly, representing Chinese Thoracic Oncology Group in China and Southwestern Oncology Group in the US.  They will share their insights of the successes of their consortium and their thoughts of cross-boarder collaboration. 

Webinar Date:

China Time: Saturday May 23th, 9 AM

US EST Time: Friday, May 22th, 9 PM

US PST Time: Friday, May 22th, 6 PM

Conference Language: English

Venue: Live Zoom Webcast

Webinar Agenda


Dr. Li Xu, Acting Chief Medical Officer Transcenta Holding

CTONG Representative

Prof. Yi-Long Wu, Guangdong Lung Cancer Institute, Guangdong Provincial People’s Hospital

SWOG Representative

Prof. Karen Kelly, UC Davis


Dr. Todd Yancey, SVP, Global Medical Affairs & New Market Development, BeiGene

Dr. Xueming Qian, Founder & CEO, MABSPACE BIOSCIENCES / Transcenta Holding

Dr. Roger Luo, Senior Vice President, Chief Development Officer, Ionova Life Science


Speakers Bio


Dr. Li Xu, Acting Chief Medical Officer Transcenta Holding

Dr. Li Xu is the Acting Chief Medical Officer at Transcenta Holding and a Venture Partner of Lilly Asia Ventures. She is the founder of Xexus A Global Biopharma Clinical Development Consulting, LLC. Prior to her current roles, Dr. Xu held positions in multi-national pharmaceutical companies, including the Vice President and Head of Oncology Clinical Development at Jiangsu Hengrui Medicine Co Ltd, the Vice President of Oncology Business Unit at Pfizer Inc., New York, NY, USA, and the Director of Medical Scientific Operations at Merck and Co., New Jersey, USA.

Dr. Li Xu is an accomplished Physician-Scientist with 20 years of leadership experiences in biopharmaceutical companies. Since she joined pharmaceutical industry, Dr. Xu has mainly worked in global oncology clinical development; led and/or participated in global clinical development programs in solid tumors as well as hematological malignancies for number of novel compounds that led to 9 successful global or China registrations and marketing for drugs treating lung, colorectal, renal, breast and gastric cancers, and hematological malignancies. She has had proven track record of designing and implementing strategies to improve performance in oncology drug clinical development and led and/or participated in delivering first or best in class oncology drugs to the market.

Dr. Xu received her M.D. from Shandong Medical College, her M.S.D. from University of Washington in Seattle and her M.B.A. from Fairleigh Dickinson University in New Jersey. She completed her Surgical Oncology Fellowship at MSKCC in New York City.


Prof. Yi-Long Wu, Guangdong Lung Cancer Institute, Guangdong Provincial People’s Hospital

Prof. Yi-Long Wu is a tenured professor of Guangdong Provincial People’s Hospital, Guangdong Academy of Medical Sciences and Guangdong Lung Cancer Institute. He is the Past President of Chinese Society of Clinical Oncology (CSCO), the Chief of the WU JIEPING Oncology Medical Foundation, the vice-director of the Precision Medicine of the Chinese Medical Doctor Association, the President of Chinese Thoracic Oncology Group(C-TONG), Board of Directors of the International Association Study of Lung Cancer(IASLC,2013-2017), a past Member of the International Affairs Committee of American Society of Clinical Oncology (ASCO).

He graduated from Sun Yat-sen University of Medical Sciences in 1982 and completed his thoracic surgery training in Germany in 1989. His main research interests are the multidisciplinary synthetic therapy on lung cancer in translation medicine and evidence-based medicine in oncology. He is leading the Chinese lung cancer research field and has been the Principal Investigator or Co-PI of more than 200 international or national multicenter clinical trials. He received several awards, including the national science and technology award, the Chinese medical science and technology award. He has contributed 22 books on cancer and has published more than 300 articles in peer-reviewed journals including J Clin Oncol, Lancet Oncol, Lancet, New Engl J Med,Cancel Cell, Ann Oncol and J Thorac Oncol. He also serves on the editorial boards of Nature Review Clinical Oncology, Annual of Oncology, Journal of Hematology and Oncology, Journal of Immunotherapy of Cancer, The Oncologist, Science Bulletin, Deputy Editor of Lung Cancer.


Prof. Karen Kelly, UC Davis

Karen Kelly, MD is a Professor of Hematology and Oncology at the University of California, Davis School of Medicine in Sacramento, California. Dr. Kelly is a recognized lung cancer expert dedicated to providing enhanced cancer care through leading-edge clinical trials. Her research spans the spectrum of the disease from prevention to treatment. Dr. Kelly has been at the forefront in the development of numerous clinical trials evaluating anticancer agents to treat lung cancer and novel compounds to prevent it. She earned her medical degree from the University of Kansas School of Medicine in 1984 and completed her internal medicine residency and oncology fellowship at the University of Colorado Health Sciences Center in Denver, Colorado in 1990. Dr. Kelly served on the faculty at the University of Colorado from 1990-2006 and at the University of Kansas from 2006-2010 before accepting her current position in 2011. Widely published, Dr. Kelly has authored or co-authored over 180 publications including original papers, reviews and book chapters. She frequently lectures on lung cancer topics, nationally and internationally. Dr. Kelly is a longstanding active member of the IASLC, currently serving on its board of directors.


Dr. Todd Yancey, SVP, Global Medical Affairs & New Market Development, BeiGene

Todd Yancey, M.D., is Senior Vice President, Global Medical Affairs and New Market Development at BeiGene. Dr. Yancey joined BeiGene in February 2017 as Senior Vice President, Global Clinical Development for Immuno-Oncology where he was instrumental in developing the global solid tumor clinical program and organization. Dr. Yancey has been a physician for almost 35 years and has spent the majority of that time in roles of increasing seniority in international biotechnology Clinical Development and Medical Affairs. He has served in a leadership role for the development or launch of numerous registered Oncology therapeutics. Previously, Dr. Yancey was Group Vice President of Global Medical Affairs at BioMarin; SVP of Global Medical Affairs at Clovis Oncology; VP of Global Medical Affairs at Medivation; and SVP of Clinical Development at Onyx. Dr. Yancey received his M.D., from the University of Virginia School of Medicine and his Bachelor of Arts in Biology and Psychology also from the University of Virginia. He completed his residency in Internal Medicine at The New York Hospital, Memorial Sloan Cancer Center and his fellowship in General Internal Medicine and HIV infection at Cornell University.


Dr. Xueming Qian, Founder & CEO, MABSPACE BIOSCIENCES / Transcenta Holding

Dr. Qian is CEO of Transcenta Holding Limited, a clinical stage biotherapeutics company with fully-integrated capabilities in research, development, regulatory and manufacturing of biologics. Transcenta was formed by merging of Mabspace Biosciences and Just Biotherapeutics Asia in 2018. Dr. Qian founded Mabspace in 2013 and served as its chairman and CEO of Mabspace Biosciences. Transcenta was formed to discover and deliver high quality innovative biologics at affordable price to patients around the world. Transcenta has over 250 plus mission driven staffs working in six global sites including Suzhou, Hangzhou, Shanghai, Beijing in China, Princeton and, Boston in US. Transcenta currently has over 10 innovative pipeline molecules in development in oncology, bone and kidney disorders. Several of them are in clinical trials in both China and US. Transcenta was backed by an elite group of investors including Lilly Asia Ventures, Arch Ventures, Temasek, Sequoia Capital China and Hillhouse Capital.

Dr. Qian has over twenty years of industrial experience in biotechnology drug discovery and development. Before starting Mabspace / Transcenta, Dr. Qian was Senior VP and R&D Head of Shenogen Pharma Group from 2010 and 2013. Dr. Qian worked more than 12 years at Amgen as principal scientist and project team leader from 1997 and 2010. Dr. Qian is the author over ten patent applications and a member of the New Drug Founder’s Club, Biologics Innovation Group, BayHelix as well as several scientific organizations such as ASCO, ESMO, AACR,ASN and Antibody Society.


Dr. Roger Luo, Senior Vice President, Chief Development Officer, Ionova Life Science

Dr. Feng (Roger) Luo has more than 20 years of experience in pharmaceutical R&D, had led and supported NDA programs of several novel oncology drugs, including EGFR inhibitor for lung cancer (Abivertinib), FGFR inhibitor for urothelial cancer (Erdafitinib), and BCR-ABL inhibitor for leukemia (Dasatinib). In addition, Dr. Luo had participated the clinical development of multiple antibody drugs including anti-EGFR antibody (Cetuximab), anti-DR5 antibody (Tigatuzumab), anti-VISTA antibody, and anti-PD-1/Tim3 dualbody. Dr. Luo also has extensive experience for licensing and business development, had participated multiple evaluation of external collaborations, partnerships, in-licensing, and acquisitions, and represented the company at industry, investor and professional conferences. He also served as the core team member to found Johnson & Johnson-Lung Cancer Center in China.

Dr. Luo is now employed by Ionova, a clinical stage biotech company, as Senior Vice President, Chief Development Office with the primary responsibilities of overseeing the China and Global Clinical Development Organization, leading clinical development programs and clinical portfolio strategy. Prior this, Dr. Luo was Senior Vice President/Chief Clinical Development Office at Adagene (2019-2020) with the primary responsibilities of overseeing the China and Global Clinical Development Organization and leading clinical development programs. Prior to Adagene, Dr. Luo was Vice President/Head of Global Clinical Development at ACEA Therapeutics (2017-2019), with the primary responsibilities of overseeing the global clinical development organization and leading global clinical programs. Prior to ACEA Therapeutics, Dr. Luo was the Asia Pacific Clinical Program Lead at Johnson & Johnson (2009-2017) with the primary responsibility of development strategy and execution. Prior to Johnson and Johnson, Dr. Luo was Senior Director/Early Clinical Program Lead at Daichi-Sankyo (2007-2009) with the primary responsibility of leading early clinical development programs. Before that, Dr. Luo worked for Bristol Myers Squibb (2000-2007) as the Clinical Pharmacology Lead to support the clinical development of Dasatinib.

Dr. Luo completed his postdoc fellowship training at Cancer Institute of New Jersey, received his Ph.D. in Clinical Pharmacology from University of North Carolina at Chapel Hill, M.S. degree in Biochemistry from Bowling Green State University and B.S. degree in Chemistry from Peking University. He is currently the executive committee member of USCACA, and is affiliated with professional organizations of AACR, ASCO, CSCO, ASH, IASLC and ASCPT.



US Chinese Anti-Cancer Association

U.S. Chinese Anti-Cancer Association (USCACA) is a non-profit professional organization founded in 2009. With members from academia, industry and government, USCACA facilitates collaboration among cancer research and physicians in the United States and China. Our current focus is on expediting novel cancer drug development by fostering clinical trial networks, sharing best practices and knowledge of clinical trial, and providing education and training opportunities. USCACA collaborates with Chinese Anti-Cancer Association, Chinese Society for Clinical Oncology, and other professional associations. Our mandate is to improve cancer treatment through research, education, and collaboration.


eChinaHealth is an integrated media for China healthcare and pharmaceutical segments. eChinaHealth services include digital platform and media, conferences and events, data and consulting, and social network and community.

eChinaHealth is exclusive China sale representation for ASCO Publications including “Journal of Clinical Oncology”, “Journal of Clinical Practice”, and “ASCO Post”, etc. eChinaHealth and ASCO plan to organize a series of ASCO Direct™ conference in China. The ASCO Direct™ program is an educational initiative that condenses highlights from ASCO Meeting into a 1-day China program, in an effort to provide Chinese doctors’ access to the most cutting-edge research discussed at ASCO meetings.





BeiGene is a biopharmaceutical company focused on developing molecularly targeted and immuno-oncology drug candidates for the treatment of cancer. Our mission is to become a global leader in the discovery, development, and commercialization of innovative, molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.


Welcome to john the ASCO China Conference WeChat Groups! You can follow up the latest on ASCO China conferences and network with fellow Chinese and global attendees. We will post the conference information including the links on recorded conference videos. Please use your WeChat to scan the QR code to join.